Multiple sclerosis in the context of the COVID-19 pandemic

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Multiple sclerosis is a serious, potentially disabling disease of the central nervous system that often affecting several areas of the brain and spinal cord at the same time. A large number of patients with this disease have been identified in Russia. The aetiology of multiple sclerosis is still under investigation. Every year, new data emerge on the influence of different factors and their interaction. Modern science is actively studying the mechanisms of multiple sclerosis progression, the role of mitochondria in inflammation and neurodegeneration, as well as the impact of COVID-19 on the possibility of development and progression of multiple sclerosis. In this review, we will consider the impact of the SARS-CoV-2 virus on the course of multiple sclerosis.

Full Text

Restricted Access

About the authors

Sergey M. Karpov

Stavropol State Medical University

Email: karpov25@rambler.ru

M.D., D. Sci. (Med.), Prof., Head of the Depart., Depart. of Neurology, Neurosurgery and Medical Genetics

Russian Federation, Stavropol

Irina A. Vyshlova

Stavropol State Medical University

Author for correspondence.
Email: irisha2801@yandex.ru
ORCID iD: 0000-0001-9187-8481
SPIN-code: 6908-7872

M.D., D. Sci. (Med.), Assoc. Prof., Depart. of Neurology, Neurosurgery and Medical Genetics

Russian Federation, Stavropol

Anna I. Klimenko

Stavropol State Medical University

Email: anyutikkovalenko@mail.ru
ORCID iD: 0000-0002-2201-7626

PhD student, Depart. of Neurology, Neurosurgery and Medical Genetics

Russian Federation, Stavropol

Evgenii A. Tkachenko

Stavropol State Medical University

Email: Evgenu.Tkachenko@mail.ru
ORCID iD: 0000-0002-4098-3887
SPIN-code: 7730-8079

student

Russian Federation, Stavropol

Rustam N. Gadaborshev

Stavropol State Medical University

Email: grn.ing@mail.ru
ORCID iD: 0000-0003-1699-3601

PhD student, Depart. of Neurology, Neurosurgery and Medical Genetics

Russian Federation, Stavropol

Akhshar I. Dzutsev

Stavropol State Medical University

Email: dzutsev76@gmail.com
ORCID iD: 0000-0002-6693-264X

PhD student, Depart. of Neurology, Neurosurgery and Medical Genetics

Russian Federation, Stavropol

References

  1. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/s0140-6736(20)30566-3.
  2. Guan WJ, Ni ZY, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032.
  3. Popova EV, Aleksandrov MI, Trubnikova IA et al. Clinical observation of the course of COVID-19 in patients with multiple sclerosis on the background of therapy with ocrelizumab: Two clinical cases. Meditsinskii sovet. 2021;(10):108–111. (In Russ.) doi: 10.21518/2079-701X-2021-10-108-111.
  4. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: Clinical aspects. Curr Opin Neurol. 2018;31(6):752–759. doi: 10.1097/WCO.0000000000000622.
  5. Yamout BI, Alroughani R. Multiple sclerosis. Semin Neurol. 2018;38(2):212–225. doi: 10.1055/s-0038-1649502.
  6. Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016;16(6):53–59. doi: 10.7861/clinmedicine.16-6-s53.
  7. Dobson R, Giovannoni G. Multiple sclerosis — a review. Eur J Neurol. 2019;26(1):27–40. doi: 10.1111/ene.13819.
  8. Walton C, King R, Rechtman L et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–1821. doi: 10.1177/1352458520970841.
  9. The Multiple Sclerosis International Federation. Atlas of MS. 3rd ed. 2020. https://www.msif.org/wp-content/uploads/2020/12/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf (access date: 15.11.2022).
  10. Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin. 2016;34(4):919–939. doi: 10.1016/j.ncl.2016.06.016.
  11. Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav. 2015;5(9):362. doi: 10.1002/brb3.362.
  12. Ministerstvo zdravookhraneniia Rossiiskoi Federatsii. Clini-cal recommendations ‘Multiple sclerosis”. 2022. р. 195. (In Russ.) https://centrems.com/downloads/Clinical_recommendations_of_the_RS-Project_submitted_to_the_MHRF.pdf (access date: 15.11.2022).
  13. Steinman L, Fox E, Hartung HP et al. Ublituximab versus Teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704–714. doi: 10.1056/NEJMoa2201904.
  14. Damal K, Stoker E, Foley JF. Optimizing therapeutics in the management of patients with multiple sclerosis: A review of drug efficacy, dosing, and mechanisms of action. Biologics. 2013;7:247–258.
  15. Ghajarzadeh M, Bonavita S. Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection? Neurol Sci. 2020;41(9):2315–2316. doi: 10.1007/s10072-020-04570-8.
  16. Landtblom AM, Berntsson SG, Boström I et al. Multiple sclerosis and COVID-19: The Swedish experience. Acta Neurol Scand. 2021;144(3):229–235. doi: 10.1111/ane.13453.
  17. Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020;43:102–195. doi: 10.1016/j.msard.2020.102195.
  18. Hada M, Mosholder AD, Leishear K et al. Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. Neurol Sci. 2022;43(3):1557–1567. doi: 10.1007/s10072-021-05846-3.
  19. Bsteh G, Bitschnau C, Hegen H et al. Multiple sclerosis and COVID-19: How many are at risk? Eur J Neurol. 2021;28(10):3369–3374. doi: 10.1111/ene.14555.
  20. Sormani MP, De Rossi N, Schiavetti I et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780–789. doi: 10.1002/ana.26028.
  21. Salter A, Fox RJ, Newsome SD et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North Ameri-can Registry of patients with multiple sclerosis. JAMA Neurol. 2021;78(6):699–708. doi: 10.1001/jamaneurol.2021.0688.
  22. Kovvuru S, Nalleballe K, Onteddu SR et al. Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic. J Neurol Sci. 2021;420:117–230. doi: 10.1016/j.jns.2020.117230.
  23. Hollen C, Bernard J. Multiple sclerosis management during the COVID-19 pandemic. Curr Neurol Neurosci Rep. 2022;22(8):537–543. doi: 10.1007/s11910-022-01211-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 75562 от 12 апреля 2019 года.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies